Literature DB >> 19531944

Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit.

Andre C Kalil1, Diana F Florescu.   

Abstract

INTRODUCTION: Cytomegalovirus is the most common viral opportunistic infection in immunocompromised patients. However, recent studies have demonstrated active cytomegalovirus infection in nonimmunosuppressed intensive care unit patients.
OBJECTIVE: To define the frequency and mortality rate associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit.
METHODS: A systematic review up to October 2008 was performed. Pooled results were analyzed by fixed- and random-effects models. Cochran Q and I2 were performed for heterogeneity.
RESULTS: Thirteen studies (n = 1258) were selected. The overall rate of active cytomegalovirus infection was 17% (95% confidence interval [CI], 11% to 24%; p < .0001; I2 = 86%). When the patients were screened for > or =5 intensive care unit days, the overall rate of infection increased to 21% (95% CI, 15% to 29%; p < .001). The infection rate for studies that used cytomegalovirus DNA/antigen for diagnosis was 20% (95% CI, 13% to 31%; p < .0001) and for studies that used culture was 12% (95% CI, 6% to 22%; p < .0001). The cytomegalovirus rate for patients with unknown serology was 7% (95% CI, 3% to 14%; p < .0001), whereas the rate for patients with positive serology was 31% (95% CI, 22% to 42%; p < .0001). The rate of infection was higher in patients with severe sepsis: 32% (95% CI, 22% to 45%; p < .0001). And in patients with high disease severity: 32% (95% CI, 23% to 42%; p < .0001). The overall mortality rate associated with active cytomegalovirus infection was 1.93 times (95% CI, 1.29 to 2.88; p = .001) as high as that without cytomegalovirus infection.
CONCLUSIONS: Active cytomegalovirus infection occurs frequently in nonimmunosuppressed patients in intensive care, especially in those with positive cytomegalovirus serology, intensive care unit stay > or =5 days, severe sepsis, and high disease severity, in whom the rate of cytomegalovirus infection is up to 36%. Mortality rate is significantly doubled with cytomegalovirus, but a cause-effect relationship cannot be established yet. A large prospective cohort study on the patient population identified by our findings is needed to define who is at the highest risk for developing active cytomegalovirus infection and to determine its effects on mortality.

Entities:  

Mesh:

Year:  2009        PMID: 19531944     DOI: 10.1097/CCM.0b013e3181a3aa43

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  73 in total

1.  Viral community-acquired pneumonia: if we do not diagnose it and do not treat it, can it still hurt us?

Authors:  Michael S Niederman
Journal:  Chest       Date:  2010-10       Impact factor: 9.410

2.  Cytomegalovirus and Epstein-Barr virus reactivation in the intensive care unit.

Authors:  O Coşkun; E Yazici; F Şahiner; A Karakaş; S Kiliç; M Tekin; C Artuk; L Yamanel; B A Beşirbellioğlu
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-07-19       Impact factor: 0.840

3.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome.

Authors:  Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

Review 4.  Impact of cytomegalovirus load on host response to sepsis.

Authors:  Thomas Marandu; Michael Dombek; Charles H Cook
Journal:  Med Microbiol Immunol       Date:  2019-04-11       Impact factor: 3.402

Review 5.  Current Understanding of Cytomegalovirus Reactivation in Critical Illness.

Authors:  Hannah Imlay; Ajit P Limaye
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

6.  Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically Ill Adults.

Authors:  Paula Lopez Roa; Joshua A Hill; Katharine A Kirby; Wendy M Leisenring; Meei-Li Huang; Tracy K Santo; Keith R Jerome; Michael Boeckh; Ajit P Limaye
Journal:  Crit Care Med       Date:  2015-07       Impact factor: 7.598

7.  Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.

Authors:  Ajit P Limaye; Renee D Stapleton; Lili Peng; Scott R Gunn; Louise E Kimball; Robert Hyzy; Matthew C Exline; D Clark Files; Peter E Morris; Stephen K Frankel; Mark E Mikkelsen; Duncan Hite; Kyle B Enfield; Jay Steingrub; James O'Brien; Polly E Parsons; Joseph Cuschieri; Richard G Wunderink; David L Hotchkin; Ying Q Chen; Gordon D Rubenfeld; Michael Boeckh
Journal:  JAMA       Date:  2017-08-22       Impact factor: 56.272

8.  Antiviral prophylaxis of cytomegalovirus reactivation in immune competent patients-the jury remains out.

Authors:  Sara A Mansfield; Charles H Cook
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

9.  Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice.

Authors:  Meghan R Forster; Joanne Trgovcich; Peter Zimmerman; Alexander Chang; Cortland Miller; Paul Klenerman; Charles H Cook
Journal:  Antiviral Res       Date:  2009-12-11       Impact factor: 5.970

10.  Top stories of 2009.

Authors:  S K Todi
Journal:  Indian J Crit Care Med       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.